ADIA Nutrition's four clinical studies on stem cell therapies get IRB approval, kidney study starts recruitment.

ADIA Nutrition announced Institutional Review Board (IRB) approval for all four of its planned clinical studies evaluating its AdiaVita™ stem cell and exosome therapies. The flagship kidney health study for chronic kidney disease has been registered on ClinicalTrials.gov and will begin recruiting participants soon. Other studies include trials on autism spectrum disorder and lower back pain, with the autism study already treating patients. These trials aim to generate clinical data supporting regenerative treatments for critical health conditions.